Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 04 November, 2011 and appeared in  MedicationType 2 DiabetesGLP-1 Receptor Agonist TherapyIssue 598

Diabetes Drug Also Reduces Inflammation

A GLP-1 drug prescribed to help patients with type 2 diabetes improve blood-sugar control also has a powerful anti-inflammatory effect, and the effect was observed within 2 hours following a single dose....

Advertisement

Dr. Paresh Dandona, a professor at the University at Buffalo School of Medicine and Biomedical Sciences, said the study of the drug exenatide, or Byetta, was designed after past observations indicated an anti-inflammatory effect, reducing plasma C-reactive protein levels, triglycerides and systolic blood pressure.

Dandona, the senior author, said in a statement that, "Our most important finding was this rapid, anti-inflammatory effect, which may lead to the inhibition of atherosclerosis, the major cause of heart attacks, strokes and gangrene in diabetics."

It was noteworthy the anti-inflammatory effect occurred independently of weight loss over the 12-week study period.

Dr. Ajay Chaudhuri said obesity is an inflammatory state and adipose tissue contributes to inflammation. If a person loses weight it can lead to an anti-inflammatory effect.

Chaudhuri, the lead author, said, "The fact that the drug caused this dramatic and comprehensive anti-inflammatory effect independent of weight loss shows that it is a primary action of the drug and is not dependent upon weight loss." "Even more importantly, a short-lived anti-inflammatory effect was observed within 2 hours following a single injection of 5 micrograms of the drug. This coincides with the peak concentration of the drug after the injection. Such a rapid and dramatic effect is rare."

Journal of Clinical Endocrinology and Metabolism, Nov. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 04 November, 2011 and appeared in  MedicationType 2 DiabetesGLP-1 Receptor Agonist TherapyIssue 598

Past five issues: Diabetes Clinical Mastery Series Issue 137 | Issue 677 | SGLT2 Special Edition Issue 2 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?

Navigate Diabetes In Control
Search Articles On Diabetes In Control